The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: A microdialyis study in olfactory bulbectomized rats

Pharmacology Biochemistry and Behavior

Volumn 97, Issue 3, 2011, Pages 444-452

  Prins, J ^a   Westphal, K G C ^a   Korte Bouws, G A H ^a   Quinton, M S ^b   Schreiber, R ^b   Olivier, B ^a,c   Korte, S M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SUNOVION PHARMACEUTICALS INC   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anhedonia; Dopamine; DOV 216,303; In vivo microdialysis; Monoamine; Olfactory bulbectomy

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; DOPAMINE; MONOAMINE; NORADRENALIN; SEROTONIN;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHRONIC DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; HIPPOCAMPUS; LOCOMOTION; MAJOR DEPRESSION; MALE; NONHUMAN; OLFACTORY BULBECTOMY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; DOPAMINE; ELECTROCHEMISTRY; LOCOMOTION; MALE; MICRODIALYSIS; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; OLFACTORY BULB; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN;

ANIMALIA; RATTUS;

EID: 78049498875     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.10.001     Document Type: Article

References (52)

1. L. Acsady, D. Arabadzisz, I. Katona, and T.F. Freund Topographic distribution of dorsal and median raphe neurons with hippocampal, septal and dual projection Acta Biol Hung 47 1996 9 19 (Pubitemid 126524691)
2. B. Beer, J. Stark, P. Krieter, P. Czobor, G. Beer, and A. Lippa DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile J Clin Pharmacol 44 2004 1360 1367 (Pubitemid 39518641)
3. M.E. Breuer, L. Groenink, R.S. Oosting, H.G. Westenberg, and B. Olivier Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats Biol Psychiatry 61 2007 990 995 (Pubitemid 46482465)
4. M.E. Breuer, J.S. Chan, R.S. Oosting, L. Groenink, S.M. Korte, and U. Campbell The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects Eur Neuropsychopharmacol 18 2008 908 916
5. M.E. Breuer, L. Groenink, R.S. Oosting, E. Buerger, M. Korte, and B. Ferger Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats Eur J Pharmacol 616 2009 134 140
6. M.E. Breuer, M.M. van Gaalen, W. Wernet, S.E. Claessens, R.S. Oosting, and B. Behl SSR149415, a non-peptide vasopressin V(1b) receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model Naunyn-Schmiedeberg's Arch Pharmacol 379 2009 101 106
7. K. Brosen, and C.A. Naranjo Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram Eur Neuropsychopharmacol 11 2001 275 283 (Pubitemid 32781006)
8. Z. Chen, and P. Skolnick Triple uptake inhibitors: therapeutic potential in depression and beyond Expert Opin Investig Drugs 16 2007 1365 1377 (Pubitemid 47491407)
9. B.M. Cohen, and R.J. Baldessarini Tolerance to therapeutic effects of antidepressants Am J Psychiatry 142 1985 489 490 (Pubitemid 15108215)
10. P.S. D'Aquila, M. Collu, G.L. Gessa, and G. Serra The role of dopamine in the mechanism of action of antidepressant drugs Eur J Pharmacol 405 2000 365 373
11. K.P. DeSanty, and C.M. Amabile Antidepressant-induced liver injury Ann Pharmacother 41 2007 1201 1211 (Pubitemid 47122557)
12. G. Di Chiara, P. Loddo, and G. Tanda Reciprocal changes in prefrontal and limbic dopamine responsiveness to aversive and rewarding stimuli after chronic mild stress: implications for the psychobiology of depression Biol Psychiatry 46 1999 1624 1633 (Pubitemid 30001604)
13. B.W. Dunlop, and C.B. Nemeroff The role of dopamine in the pathophysiology of depression Arch Gen Psychiatry 64 2007 327 337 (Pubitemid 46376789)
14. B.J. Everitt, and T.W. Robbins Neural systems of reinforcement for drug addiction: from actions to habits to compulsion Nat Neurosci 8 2005 1481 1489 (Pubitemid 41573659)
15. A. Gasbarri, A. Sulli, and M.G. Packard The dopaminergic mesencephalic projections to the hippocampal formation in the rat Prog Neuropsychopharmacol Biol Psychiatry 21 1997 1 22 (Pubitemid 27145410)
16. W.J. Giardina, and R.J. Radek Effects of imipramine on the nocturnal behavior of bilateral olfactory bulbectomized rats Biol Psychiatry 29 1991 1200 1208
17. J.F. Goldberg, K.E. Burdick, and C.J. Endick Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression Am J Psychiatry 161 2004 564 566 (Pubitemid 38326114)
18. B.P. Guiard, M. El Mansari, and P. Blier Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors Curr Drug Targets 10 2009 1069 1084
19. S. Gupta, J.L. Vincent, and B. Frank Pramipexole: augmentation in the treatment of depressive symptoms CNS Spectr 11 2006 172 175
20. S. Hjorth, and S.B. Auerbach Lack of 5-HT1A autoreceptor desensitization following chronic citalopram treatment, as determined by in vivo microdialysis Neuropharmacology 33 1994 331 334
21. M.M. Katz, J.W. Maas, A. Frazer, S.H. Koslow, C.L. Bowden, and N. Berman Drug-induced actions on brain neurotransmitter systems and changes in the behaviors and emotions of depressed patients Neuropsychopharmacology 11 1994 89 100 (Pubitemid 24334064)
22. M.M. Katz, J.L. Tekell, C.L. Bowden, S. Brannan, J.P. Houston, and N. Berman Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression Neuropsychopharmacology 29 2004 566 579 (Pubitemid 38365934)
23. J.P. Kelly, A.S. Wrynn, and B.E. Leonard The olfactory bulbectomized rat as a model of depression: an update Pharmacol Ther 74 1997 299 316 (Pubitemid 27425352)
24. I. Kirsch, B.J. Deacon, T.B. Huedo-Medina, A. Scoboria, T.J. Moore, and B.T. Johnson Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration PLoS Med 5 2008 e45
25. D. Klein, and T.S. Brown Exploratory behavior and spontaneous alternation in blind and anosmic rats J Comp Physiol Psychol 68 1969 107 110
26. M. Koenigs, and J. Grafman The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex Behav Brain Res 201 2009 239 243
27. G.F. Koob, and N.D. Volkow Neurocircuitry of addiction Neuropsychopharmacology 35 2010 217 238
28. G.A. Korte-Bouws, S.M. Korte, E.R. De Kloet, and B. Bohus Blockade of corticosterone synthesis reduces serotonin turnover in the dorsal hippocampus of the rat as measured by microdialysis J Neuroendocrinol 8 1996 877 881 (Pubitemid 26362801)
29. M.R. Lemke, H.M. Brecht, J. Koester, and H. Reichmann Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease J Neurol Sci 248 2006 266 270 (Pubitemid 44754866)
30. I. Lucki The forced swimming test as a model for core and component behavioral effects of antidepressant drugs Behav Pharmacol 8 1997 523 532 (Pubitemid 27504702)
31. I. Malagie, A.C. Trillat, E. Douvier, M.C. Anmella, M.C. Dessalles, and C. Jacquot Regional differences in the effect of the combined treatment of WAY 100635 and fluoxetine: an in vivo microdialysis study Naunyn-Schmiedeberg's Arch Pharmacol 354 1996 785 790 (Pubitemid 26414081)
32. F. Micheli, P. Cavanni, R. Arban, R. Benedetti, B. Bertani, and M. Bettati 1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors J Med Chem 53 2010 2534 2551
33. C.A. Naranjo, L.K. Tremblay, and U.E. Busto The role of the brain reward system in depression Prog Neuropsychopharmacol Biol Psychiatry 25 2001 781 823 (Pubitemid 32374967)
34. E.J. Nestler, and W.A. Carlezon Jr. The mesolimbic dopamine reward circuit in depression Biol Psychiatry 59 2006 1151 1159 (Pubitemid 44192421)
35. P. Popik, M. Krawczyk, K. Golembiowska, G. Nowak, A. Janowsky, and P. Skolnick Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677 Cell Mol Neurobiol 26 2006 857 873
36. J. Prins, D.A. Denys, K.G. Westphal, G.A. Korte-Bouws, M.S. Quinton, and R. Schreiber The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats Eur J Pharmacol 633 2010 55 61
37. C.L. Richman, R. Gulkin, and K. Knoblock Effects of bulbectomization, strain, and gentling on emotionality and exploratory behavior in rats Physiol Behav 8 1972 447 452
38. T.W. Robbins, and A.F. Arnsten The neuropsychopharmacology of fronto-executive function: monoaminergic modulation Annu Rev Neurosci 32 2009 267 287
39. A.J. Romanides, P. Duffy, and P.W. Kalivas Glutamatergic and dopaminergic afferents to the prefrontal cortex regulate spatial working memory in rats Neuroscience 92 1999 97 106 (Pubitemid 29249021)
40. T. Romeas, M.C. Morissette, O. Mnie-Filali, G. Pineyro, and S.M. Boye Simultaneous anhedonia and exaggerated locomotor activation in an animal model of depression Psychopharmacology (Berl) 205 2009 293 303
41. J.J. Schildkraut The catecholamine hypothesis of affective disorders: a review of supporting evidence Am J Psychiatry 122 1965 509 522
42. P. Skolnick, P. Popik, A. Janowsky, B. Beer, and A.S. Lippa Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor Eur J Pharmacol 461 2003 99 104 (Pubitemid 36174028)
43. P. Skolnick, P. Krieter, J. Tizzano, A. Basile, P. Popik, and P. Czobor Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor CNS Drug Rev 12 2006 123 134 (Pubitemid 44300380)
44. D.A. Slattery, A. Markou, and J.F. Cryan Evaluation of reward processes in an animal model of depression Psychopharmacology (Berl) 190 2007 555 568 (Pubitemid 46204472)
45. K. Solomons, S. Gooch, and A. Wong Toxicity with selective serotonin reuptake inhibitors Am J Psychiatry 162 2005 1225 (Pubitemid 40770713)
46. C. Song, and B.E. Leonard The olfactory bulbectomised rat as a model of depression Neurosci Biobehav Rev 29 2005 627 647 (Pubitemid 40755458)
47. D.C. Steffens, K.R. Krishnan, and M.J. Helms Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis Depress Anxiety 6 1997 10 18 (Pubitemid 28079906)
48. T. Suhara, A. Takano, Y. Sudo, T. Ichimiya, M. Inoue, and F. Yasuno High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography Arch Gen Psychiatry 60 2003 386 391 (Pubitemid 36402999)
49. H.M. van der Stelt, M.E. Breuer, B. Olivier, and H.G. Westenberg Permanent deficits in serotonergic functioning of olfactory bulbectomized rats: an in vivo microdialysis study Biol Psychiatry 57 2005 1061 1067 (Pubitemid 40603089)
50. L.A. Verhagen, M.C. Luijendijk, G.A. Korte-Bouws, S.M. Korte, and R.A. Adan Dopamine and serotonin release in the nucleus accumbens during starvation-induced hyperactivity Eur Neuropsychopharmacol 19 2009 309 316
51. P. Willner, A. Towell, D. Sampson, S. Sophokleous, and R. Muscat Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant Psychopharmacology (Berl) 93 1987 358 364 (Pubitemid 17160661)
52. P. Willner, R. Muscat, and M. Papp Chronic mild stress-induced anhedonia: a realistic animal model of depression Neurosci Biobehav Rev 16 1992 525 534